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Low serum levels of 25-hydroxy vitamin D frequently occur
after renal transplantation, but few studies have evaluated
the effects of normalizing this on serum parathyroid
hormone and calcium levels or urinary calcium excretion. To
determine this we compared the outcomes of 94 renal
transplant patients with low 25-hydroxy vitamin D and
normal serum calcium levels who were either treated or not
with cholecalciferol every 2 weeks for 2 months (intensive
phase) followed by an every other month maintenance
phase. The biological characteristics of the two equally
divided patient groups did not differ before treatment. After
the intensive phase, serum 25-hydroxy vitamin D levels were
normalized in all but 3 patients and the serum parathyroid
hormone decreased and calcium levels increased with no
severe adverse effects. During the maintenance phase, the
serum 25-hydroxy vitamin D level decreased but remained
significantly higher than in controls. In the control group, the
serum 25-hydroxy vitamin D concentration increased slightly
but became normal in only three patients. Serum 25-hydroxy
vitamin D levels were significantly higher and parathyroid
hormone levels were lower in treated patients compared to
controls one year following transplant. Hence, cholecalciferol
treatment significantly increased serum 25-hydroxy vitamin
D and decreased parathyroid hormone levels with no adverse
effects in 25-hydroxy vitamin D–deficient renal transplant
patients.
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Low serum 25-hydroxyvitamin (25-OH) vitamin D concen-
tration is a frequent finding in renal transplant recipients
(RTRs)1–3 that can generate secondary hyperparathyroid-
ism.4,5 Several studies suggest that in non-renal transplant
subjects, serum 25-OH vitamin D concentration should be
maintained above 30 ng/ml6–9 to prevent serum parathor-
mone (PTH) levels from increasing. In most RTRs, serum 25-
OH vitamin D concentration is below this value in the
months or years following transplantation.1–3 This may be
because of various causes: (1) insufficient vitamin D
supplementation in dialysis and after transplantation, (2)
reduced sun exposure recommended to RTR to prevent skin
cancers, and (3) increased 25-OH vitamin D catabolism
induced by immunosuppressive drugs and increased fibro-
blast growth factor-23 secretion, which is a common finding
in RTR.10,11 Indeed, in rats, fibroblast growth factor-23
stimulates 24 hydroxylase enzyme activity, increases 25-OH
vitamin D conversion into 24,25-(OH)2 vitamin D, and
decreases serum 25-OH vitamin D concentration.12 In RTR,
as in nontransplant populations, low 25-OH vitamin D levels
may be associated with osteomalacia, osteoporosis, and may
increase the risks of fractures,13 cancers,7 autoimmune,7 and
cardiovascular diseases.14,15 The National Kidney Founda-
tion/Kidney Disease Outcomes Quality Initiative (NKF-
KDOQI) guidelines recommend vitamin D supplementation
when serum 25-OH vitamin D concentration is lower than
30 ng/ml in patients with chronic kidney disease stage 3 or 4.
According to these guidelines, RTRs should be managed as
non-transplant chronic kidney disease patients with similar
glomerular filtration rate (GFR) for bone and mineral
metabolism.16
Despite these recommendations, most RTRs do not
receive vitamin D supplementation for at least two reasons:
first, it is unknown if vitamin D supplements at the doses
required to achieve 25-OH vitamin D concentrations above
30 ng/ml could induce hypercalcemia, hypercalciuria, or
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hyperphosphatemia, all disorders that could have adverse
outcomes on renal function and patient survival. Second, it is
uncertain if increasing serum 25-OH vitamin D concentra-
tion above 30 ng/ml will reduce serum PTH concentration
in RTR.
In our department, until 2006 RTRs were not treated with
25-OH vitamin D during the first year following renal
transplantation. From May 2006 vitamin D supplements
were given in the absence of hypercalcemia in all renal
transplants with serum 25-OH vitamin D concentration
below 30 ng/ml 3 months after renal transplantation. In this
study we evaluated the effects of the treatment by
cholecalciferol, a precursor of 25-OH vitamin D, on serum
25-OH vitamin D, PTH levels, and on calcium–phosphate
balance in 47 patients and compared these results with those
obtained in another group of 47 RTRs who did not receive
vitamin D supplementation.
RESULTS
Patient characteristics
Patient clinical characteristics are presented in Table 1.
Among the patients who received a renal transplant in our
department since May 2006, 49 had normal or low serum
calcium concentrations and 25-OH vitamin D levels below
30 ng/ml at M3 and were consequently treated with
cholecalciferol according to the regimen described in
‘Materials and Methods’. Two patients were excluded from
the analyses because of the lack of compliance to treatment. A
total of 47 patients transplanted from May 2005 to December
2005 met the criteria described above and were not
supplemented with vitamin D. These 47 untreated patients
were considered as a control group for the statistical analyses.
Treated and untreated patients did not statistically differ for
age, gender immunosuppressive treatment, initial nephro-
pathy, and number of acute rejection (Table 1).
At M3 biological characteristics of treated and untreated
patients were similar as shown in Table 2.
Evolution of calcium–phosphate parameters during the
intensive phase treatment with cholecalciferol
From month 4 (M4) to month 6 (M6) the treated patients
received cholecalciferol 100,000 IU every 2 weeks (intensive
phase). As shown in Figure 1, median serum 25-OH vitamin
D concentration increased significantly at M6 compared to
M3 (M3: median 14 ng/ml, range 5–30; M6: median 43, range
16–72; Po0.0001; Figure 1a) and reached values above 30 ng/
ml in all but three patients. This was associated with a
significant decrease in serum PTH concentration between M3
and M6 (M3: median 76 pg/ml, range 19–668; M6: median
63, range 14–364; P¼ 0.028; Figure 1b). Serum calcium
concentration increased significantly from M3 to M6 (M3:
median 2.29, range 2.08–2.51 mmol/l; M6: median 2.42, range
2.18–2.71 mmol/l; Po0.001; Figure 1c) but remained within
the normal range, below 2.70 mmol/l, in all but one patient.
Serum phosphate levels moderately rose from 0.78 mmol/l
(range 0.56–1.30) to 1.04 mmol/l (range 0.71–1.53)
(Po0.0001; Figure 1d).
We observed no case of hypercalciuria induced by the
cholecalciferol treatment. At M3 one patient exhibited fasting
hypercalciuria that persisted at M6. Median fasting urinary
calcium excretion did not change significantly between M3
and M6 (M3: median 0.09, range 0.003–1.09 mmol/l; M6:
median 0.12, range 0.01–1.22 mmol/l; Figure 1e).
Effects of cholecalciferol supplementation at M12
After M6, the treated patients received cholecalciferol
100,000 IU every other month (maintenance phase). In this
group serum 25-OH vitamin D concentration significantly
decreased from M6 to M12 but remained above M3 values
(Figure 1a). At M12 25-OH vitamin D concentration
remained above 30 ng/ml in only 24 treated subjects (51%).
The decrease in serum 25-OH vitamin D concentration
between M6 and M12 (Figure 1a) was associated with a
significant decrease in mean serum calcium (Figure 1c) and
phosphate (Figure 1e) concentrations whereas median serum
PTH concentration (Figure 1b) and urinary Ca/creatinine
Table 1 | Demographic and treatment characteristics
Treated
patients
Untreated
patients P
Recipient age 46.82±2.18 45.30±2.18 NS
Recipient gender (M/F) 29/18 28/19 NS
Immunosuppressive regimen NS
Biological induction (D0) 98% 100% NS
Cyclosporine (M3/M12) (n, %) 13 (28)/16 (35) 22 (47)/15 (32) NS
Tacrolimus (M3/M12) (n, %) 30 (65)/30 (65) 24 (51)/29 (62) NS
Steroid dose (M3/M12) (mg) 9.8±7.5/5.9±4.0 10.7±7.9/7.8±3.7 NS
Acute rejection incidence 20% 25.5% NS
Initial nephropathy
Chronic glomerulonephritis 22 12 NS
Polycystic disease 5 8
Chronic interstitial nephritis 3 5
Uropathy 6 4
Diabetic nephropathy 2 5
Vascular nephropathy 2 6
NA 7 7
F, female; M, male; NA, not available; NS, not significant.
Table 2 | Biochemical parameters at month 3, before
cholecalciferol therapy was initiated in the treated group
Treated
group
(n=47)
Untreated
group
(n=47) P
Month 3
Serum Ca (mmol/l) 2.29 (2.08–2.51) 2.30 (2.05–2.52) NS
Serum phosphate (mmol/l) 0.78 (0.56–1.30) 0.76 (0.37–1.13) NS
PTH (pg/ml) 68 (19–668) 78 (24–346) NS
25-OH vitamin D (ng/ml) 14 (5–30) 12 (4–28) NS
Urinary Ca/Creat
(mmol/mmol)
0.09 (0.003–1.09) 0.08 (0.006–0.52) NS
GFR (ml/min) 58 (24–106) 59 (25–92) NS
GFR, glomerular filtration rate; NS, not significant; PTH, parathormone. All
differences were nonsignificant.
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ratio (Figure 1e) did not change significantly. At M12 all
treated patients had serum calcium concentration below
2.70 mmol/l, and normal urinary calcium excretion.
GFR did not significantly vary between M3 and M12 (M3:
median 58 ml/min, range 24–106; M12: median 56 ml/min,
range 19–93, P¼ 0.104).
Modifications of calcium–phosphate parameters between M3
and M12 in patients who did not receive cholecalciferol
Serum 25-OH vitamin D concentration slightly but sig-
nificantly increased between M3 and M12 in the patients who
did not received cholecalciferol supplementation (M3:
median 12 ng/ml, range 4–28; M12 median 14 ng/ml, range
4–46, P¼ 0.0043, Wilcoxon matched-pairs test). This slight
increase in 25-OH vitamin D concentration in untreated
patients was not accompanied by significant changes of
serum PTH (Figure 2b), calcium or phosphate concentra-
tions (Figure 2c), or urinary calcium excretion (Figure 2d)
between M3 and M12.
GFR remained stable (M3: median 59 ml/min, range
25–92; M12: median 59 ml/min, range 27–101, P¼ 0.946).
Comparison of treated and untreated patients at M12
At M3 the two groups of patients did not differ. The numbers
of patients with serum PTH concentration within the values
recommended by the NKF-KDOQI guidelines were not
statistically different between the two groups (Table 3). At
M12 serum 25-OH vitamin D concentrations were signifi-
cantly higher in treated than in untreated patients (Figure 3a,
Po0.0001, Mann–Whitney test). Serum PTH concentration
was significantly lower and serum calcium concentration was
significantly higher in treated patients than in untreated
subjects (Figure 3b and c), and the number of patients with
serum PTH concentration within the NKF-KDOQI recom-
mended values was significantly higher in the treated group
(Table 3). Serum phosphate concentration and urinary
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Figure 1 | Modifications of relevant parameters with
cholecalciferol treatment among M3, M6, and M12.
Cholecalciferol supplementation was started at month 4. (a)
Serum calcidiol concentration increased between M3 and M6,
then decreased between M6 and M12. Serum calcidiol
concentrations were greater at M12 than at M3. (b) Serum PTH
concentrations decreased from M3 to M6, then remained stable.
(c) Serum calcium concentration increased between M3 and M6,
then decreased again beyond M6. (d) Serum phosphate
concentration increased from M3 to M6, then decreased but
remained greater at M12 than at M3. (e) Urinary calcium excretion
did not change significantly with treatment. Results are expressed
as median and range. Groups were compared with the use of
Friedman test and Wilcoxon matched-pairs test as post hoc test.
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Figure 2 | Changes of relevant biochemical parameters
between M3 and M12 in patients not treated with
cholecalciferol. (a, d) Serum calcidiol and phosphate
concentrations slightly but significantly augment with time.
(b, c, e) Serum PTH and calcium concentrations and urinary
calcium excretion did not change significantly. Results are
expressed as median and range. Groups were compared with the
use of Wilcoxon matched-pairs test.
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calcium excretion did not differ between the two groups at
M12 (Figure 3d and e). At M12 the number of patients with
25-OH vitamin D concentration above 30 ng/ml was
significantly higher in the group who received cholecalciferol
(24/47 versus 3/47, Po0.0001, w2-test). GFR was not
different between the two groups (treated median 56 ml/
min, range 19–93 ml/min; untreated median 59 ml/min,
range 27–101, P¼ 0.267).
DISCUSSION
This study shows that treating RTRs with four doses of
100,000 IU cholecalciferol from M4 to M6 after transplanta-
tion increases serum 25-OH vitamin D concentration above
30 ng/ml in almost all patients, decreases serum PTH levels,
and has no adverse effects on calcium and phosphate
concentrations. This study also indicates that the dose of
cholecalciferol used during the maintenance phase was
insufficient to maintain serum 25-OH vitamin D concentra-
tion above 30 ng/ml in half of the patients.
In the absence of cholecalciferol supplementation, serum
25-OH vitamin D concentration slightly increased within the
first year following renal transplantation. However only three
patients of the control group had 25-OH vitamin D levels
above 30 ng/ml at M12 and serum calcium and PTH levels
remained below those of RTR of the treated group. This
confirms that common diets do not bring enough vitamin D
to normalize vitamin D status in RTRs.
The threshold of 30 ng/ml for serum 25-OH vitamin D
concentration was chosen on the basis of data showing that
increasing serum 25-OH vitamin D concentration above such
levels results in a decrease in serum PTH levels in non-
RTR.7,13,17,18 Our data indicate that this threshold is relevant
in RTR, as the increase in serum 25-OH vitamin D
concentration at M6 was associated with a decrease in serum
PTH levels and an increase in calcium concentration.
The decrease in serum PTH concentration may be due to
an increase in 1,25(OH)2 vitamin D production in the kidney
or in the parathyroid glands. This may also result from a
direct effect of 25-OH vitamin D on PTH synthesis. Indeed
Ritter et al.19 reported that 25-OH vitamin D repressed PTH
gene transcription and PTH secretion by activating vitamin
D receptor in bovine parathyroid cells.
Several studies report associations between low 25-OH
vitamin D plasma concentrations and cardiovascular disease
or cancer incidence and a decrease in the frequencies of these
disorders in subjects treated with vitamin D.20–23 The impact
of the improvement of 25-OH vitamin D plasma concentra-
tions on the risks of bone fracture, muscle strength,
cardiovascular morbidity or mortality, and cancer occur-
rences in RTR remains to be established in larger studies with
longer follow-up.
In most RTRs, GFR and proximal tubule functions are
often altered, which may hamper 25-OH vitamin D
hydroxylation into calcitriol. Consequently, the threshold
for suitable 25-OH vitamin D concentration may be higher
than that recommended for healthy subjects. We cannot
determine from our data whether increasing serum 25-OH
vitamin D concentration above this threshold would result in
a further decrease in serum PTH concentration in renal
recipients.
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Figure 3 | Comparisons of relevant biochemical parameters at
M12 between patients treated (circles) and not treated
(squares) with cholecalciferol. (a, c) Serum calcidiol and calcium
concentration were significantly lower in untreated than in
treated patients. (b) Serum PTH levels were higher at M12 in
untreated than in treated patients at M12. (d, e) Serum phosphate
concentration and urinary calcium excretion were not different
between the two groups at M12.
Table 3 | Number of cholecalciferol-treated or nontreated
patients with serum PTH concentration within (KDOQI+) or
not (KDOQI) KDOQI recommended values according to their
GFR at M3 and M12
M3 M12
Treated
group
Control
group
Treated
group
Control
group
KDOQI+ 24 19 34 18
KDOQI 23 28 13 29
KDOQI, Kidney Disease Outcomes Quality Initiative. At M3 the number of patients
with serum PTH concentration within KDOQI recommended value was not different
between the two groups (w2, P=0.41). At M12 the number of patients with serum
PTH concentration within recommended KDOQI range was significantly higher in
the treated group (w2, P=0.002).
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The achievement of the 25-OH vitamin D concentration
threshold required high doses of cholecalciferol. We used the
vitamin D doses recommended by Holick7 to treat vitamin D
deficiency in patients with chronic kidney disease. With
similar doses Adewoye et al.24 corrected vitamin D deficiency
in patients with sickle cell disease. The use of lower doses of
cholecalciferol (25,000 IU once a month) as reported by
Wissing et al.25 failed to correct 25-OH vitamin D
insufficiency in renal transplants.
During the maintenance treatment phase, from M6 to
M12, we reduced the doses of cholecalciferol supplementa-
tion. Although serum 25-OH vitamin D concentration was
above 30 ng/ml in almost all patients at M6, the dosage of
cholecalciferol used from M6 to M12 was insufficient to
maintain 25-OH vitamin D concentration above the target in
49% of patients, resulting in a significant decrease in serum
calcium levels. This finding suggests that RTRs have
important needs of vitamin D to maintain calcium–
phosphate balance. In a recent review Holick7 suggested a
maintenance dose of 100,000 IU/month of cholecalciferol in
patients with chronic kidney diseases, our data support this
recommendation. Further studies are needed to determine
the optimal cholecalciferol dosage required to maintain
serum 25-OH vitamin D concentration above 30 ng/ml in
these patients. However, our data suggest that measurements
of serum 25-OH vitamin D concentrations should be
performed at least three times in the first year following
renal transplantation to adjust cholecalciferol treatment to
achieve the targeted 25-OH vitamin D concentration.
Generally, GFR is below normal values in most of RTRs,
and inappropriate vitamin D supplementation might induce
hypercalcemia, hyperphosphatemia, or hypercalciuria. Our
results indicate that our treatment procedure to reverse
vitamin D insufficiency does not induce those adverse effects.
Dosages similar to those used in the present study and
associated with oral calcium supplementation in some
subjects did not induce adverse effects in non-renal
transplant patients.26–28 Recent studies indicate that toxicity
occurs for serum 25-OH vitamin D concentration beyond
200 ng/ml, the maximal serum 25-OH vitamin D concentra-
tion reached in our study was far below that value.29,30
In summary, we show that vitamin D deficiency persists 1
year after renal transplantation in the absence of treatment
and that the increase in serum 25-OH vitamin D concentra-
tion above 30 ng/ml requires high dose of cholecalciferol and
improves secondary hyperparathyroidism in renal transplant.
This goal can be reached without adverse effects.
MATERIALS AND METHODS
Patients
From May 2006 to December 2006, 49 adult patients were
transplanted in our department and received cholecalciferol
treatment according to a regimen detailed below, because they had
serum 25-OH vitamin D levels below 30 ng/ml 3 months after
transplantation. None of these patients were hypercalcemic (serum
calcium concentration o2.70 mmol/l) when cholecalciferol
treatment was started. From May 2005 to December 2005, 47 adult
patients had a renal transplantation in our department, and 25-OH
vitamin D levels below 30 ng/ml in the absence of hypercalcemia and
did not receive vitamin D supplementation. These latter patients
were considered as a control group to compare the effects of
cholecalciferol on calcium–phosphate balance and serum PTH
concentration.
Cholecalciferol treatment regimen
The group of vitamin D-treated RTRs received four oral doses of
100,000 IU cholecalciferol, once every 2 weeks from M4 to M6 after
renal transplantation (intensive phase), then every 2 months until
M12 (maintenance phase).
The group of RTRs who had no vitamin D supplementation had
the same follow up at M3 and M12 but did not receive
cholecalciferol treatment.
Patient follow-up
At M3 and M12, all patients had similar investigation including GFR
measurement by iohexol clearance, serum calcium concentration,
serum phosphate, PTH, 25-OH vitamin D, calcitriol levels, and urinary
calcium excretion expressed as urinary calcium/creatinine ratio.
At M6, which corresponds to the end of the intensive treatment
period for treated patients, we measured in all treated patients
serum calcium, phosphate, 25-OH vitamin D and PTH levels, and
urinary calcium excretion (calcium/creatinine ratio). These mea-
surements were performed 2 weeks after the last dose of
cholecalciferol.
Patient compliance to treatment was assessed by questioning.
Biochemistry measurements
Calcium, phosphate, and creatinine concentrations were measured
using standard methods.
Serum PTH level was measured with immunochemiluminescent
assays performed on the Elecsys analyzer (Roche Diagnostics,
Meylan, France).
25-OH vitamin D concentration was measured by radio-
immunoassay (DiaSorin, Stillwater, MN, USA).
Statistical analysis
Results are expressed as median and range for quantitative variables.
Quantitative variables were compared using nonparametric tests.
Multiple paired comparisons were performed with the use of
Friedman test and Wilcoxon matched-pairs test as post hoc test. To
compare two paired values we performed Wilcoxon matched-pairs
test. We used Mann–Whitney test to compare values of two unpaired
groups.
Categorical variables were compared using w2-test.
Type 1 error ao0.05 was considered as statistically significant.
All comparisons were performed with the use of GraphPad
InStat software for Macintosh.
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